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Bullous pemphigoid is the most common autoimmune 
blistering skin disease, and incidence is on the rise, due at 
least in part to its association with older age.1,2 Treatment 
of bullous pemphigoid presents a challenge to the 
clinician, as first-line treatment regimens—either oral 
corticosteroids or whole body application of super-potent 
topical steroids—result in substantial morbidity and 
mortality or present logistical challenges in the elderly.3
Few trials have compared therapies for bullous 
pemphigoid. A previous landmark study4 found that 
whole-body topical application of the super-potent 
corticosteroid clobetasol propionate was at least as 
effective as oral prednisone for disease control at 
3 weeks (and more effective for extensive disease). 
Notably, clobetasol proprionate treatment was 
associated with a significant reduction in mortality over 
52 weeks compared with high-dose (1 mg/kg per day) 
but not medium-dose prednisone (0·5 mg/kg per day). 
Consistent with dose-dependent systemic absorption 
of topical steroids, reducing the dose of topical steroids 
provided a similar degree of disease control but with 
reduced morbidity and mortality.5 Tetracyclines have 
been used in dermatology for some time for their anti-
inflammatory properties.6 The only previous study 
comparing tetracyclines with corticosteroids in bullous 
pemphigoid was terminated early and the results, 
although promising, were not statistically significant.7
In The Lancet, Hywel Williams and colleagues8 report 
the results of the largest multicentre trial comparing oral 
treatments for bullous pemphigoid; the investigators 
and participating sites should be congratulated for 
completing this valuable study. Using a non-inferiority 
trial design, they tested the hypothesis that 200 mg/day 
oral doxycycline is not inferior in effectiveness to oral 
prednisolone (0·5 mg/kg per day) and that doxycycline 
is less likely to result in severe adverse effects. 
Participants were allowed to apply up to 30 g per week 
of potent topical corticosteroids to localised lesions for 
the first 3 weeks, and after 6 weeks. A high proportion 
of participants were available for analysis at 6 weeks 
although, perhaps not unexpectedly, a substantial 
number dropped out by week 52. Rates of withdrawal 
were balanced between the two treatment groups.
So what were the major findings? The modified 
intention-to-treat analysis showed that disease 
control at 6 weeks was achieved by 91% (92 of 101) 
of participants starting prednisolone compared with 
74% (83 of 112) starting doxycycline—an adjusted 
difference (by baseline severity of bullous pemphigoid 
and Karnofsky score) of 18·6% (90% CI 11·1–26·1). In 
terms of safety, this trial underscored the adverse event 
profile of systemic steroids for bullous pemphigoid: 
36% (41 of 113) of participants starting medium-dose 
oral prednisolone developed a serious adverse event 
over 52 weeks compared with 18% (22 of 121) of 
participants starting doxycycline—an adjusted difference 
of 19·0% (95% CI 7·9–30·1). In agreement with this, 
and previous studies,5,7 treatment-related deaths were 
greater in the prednisolone group (11 deaths) compared 
with the doxycycline group (three deaths).
So how should these data be interpreted? Some help 
is provided within the protocol and statistical analysis 
plan9 and by an earlier publication from the group that 
considers, in advance, possible outcomes from this 
trial.10 Additionally, it is important to consider how the 
trial was powered and how the non-inferiority margins 
were determined and set.11,12 It appears that the trial was 
primarily powered to detect a 20% difference in grade 3, 
4, and 5 side-effects.9 Achieving a consensus around the 
setting of the non-inferiority margin is recognised to 
be challenging. The authors commendably addressed 
this in part by undertaking a survey of dermatologists 
through a national group (the UK Dermatology Clinical 
Trials Network; appendix p 18).13 The results of this survey 
suggested that UK dermatologists were willing to accept 
a 25% reduction in effectiveness if this was balanced 
against a 10% reduction in mortality rate for “tetracycline 
to have potential as a primary treatment for bullous 
pemphigoid”.13 However, it is not entirely clear how the 
data from the survey fed into the setting of the primary 
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endpoints or if the sample size was sufficient to detect a 
clinically relevant non-inferiority effectiveness margin. 
Nevertheless, it seems reasonable to move to a broader 
definition of adverse events (including grades 3–5) and 
to increase this rate to 20%. Although guidelines for 
the reporting of non-inferiority trials are not entirely 
consistent,11 the non-inferiority margin is often informed 
by the minimally clinically relevant difference12 (in this 
case 25% for effectiveness) such that to reject the null 
hypothesis (and conclude non-inferiority), the trial 
would need to provide data where the CI does not cross 
this boundary. However, the authors interpret the 
25% difference as a point estimate and extend the non-
inferiority margin to 37%—quite a large difference but 
one that was achievable from recruiting 128 participants 
per group. Together, this suggests that the trial might 
have been underpowered for non-inferiority at a clinically 
relevant difference of effectiveness.
Overall, the data look interesting and, for now, 
we are left with the conclusion that doxycycline is 
non-inferior to prednisolone in effectiveness at a 
difference of between 11·1% and 26·1% (as set by a 
90% CI). The secondary measures of effectiveness at 
6 weeks also supported a difference of more than 30% 
in favour of prednisolone and the Kaplan-Meier curve 
of time to change in treatment (appendix p 10)8 clearly 
favours oral prednisolone over doxycycline. It would be 
interesting to investigate whether any baseline clinical 
features or biomarkers might differentially predict 
treatment response. Finally, although the authors 
aimed to restrict the use of topical corticosteroids 
for symptomatic relief, we do not know whether the 
amount applied by both groups was the same. Systemic 
absorption from topical corticosteroids does occur, and 
this must be kept in mind when interpreting disease 
control, morbidity, and mortality.
In conclusion, doxycycline is clearly safer than 
prednisolone for the treatment of bullous pemphigoid 
and demonstrates a reduced success rate, based on 
achieving three or fewer blisters, at 6 weeks. The 
evidence for non-inferiority is subjective, dependent on 
the definition of the clinically relevant non-inferiority 
boundary. However, given the natural history of bullous 
pemphigoid,3 and previous responses to topical treatment 
alone,4,5 it is rational to deduce that doxycycline is at 
least partly effective. So how will this trial affect the 
management of bullous pemphigoid in clinical practice? 
Importantly, the primary endpoint for effectiveness in 
this trial was at 6 weeks. So it would seem reasonable 
to introduce doxycycline initially in combination with 
potent (or super-potent)4 topical steroids; if control is 
inadequate, treatment can then be escalated to systemic 
steroids (although this was not covered in the trial 
design). An alternative strategy, identified by the authors 
as a potential future trial, would be to start all patients 
on prednisolone to gain initial control, and then consider 
doxycycline as a potential maintenance treatment—
with patients randomly assigned to continuation of oral 
corticosteroids or doxycycline.
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There are many uncertainties in global health. Major 
policy changes risk affecting women’s reproductive 
health, internal displacement and refugee crises are 
raging in many parts of the world, and weak public 
health systems are not readily responsive to emerging 
health threats. Many countries face fragility, conflict, and 
economic upheavals. But there is also inspiration and 
hope in the amazing resilience of communities, as seen 
in post-Ebola west African countries, and in the power 
of voice and collective action among informed citizens 
who are advocating for sexual and reproductive health 
and rights for all women. Most importantly, we have a 
unique opportunity to make an indelible and irreversible 
impact on the favourable odds of women, children, and 
adolescents surviving and thriving.1,2
In recent decades, some of the world’s poorest 
countries, with much support from donors, have made 
progress in improving the health of their people. But 
they will be unprepared today and for the future without 
more coordinated and aligned country-driven efforts 
to invest in delivering the highest impact health inter-
ventions, addressing systems barriers, and tackling social 
determinants of health. They can save and improve 
many more lives, and could do so more efficiently, 
with greater reach, equity, and sustainability. Smart, 
scaled, and sustainable financing is needed to support 
these countries’ efforts to save and improve the lives 
of women, children, and adolescents in their poorest 
communities, which calls for a transformational change 
in financing for development. 
To respond to the tide of global change and prepare for 
the new development era, the UN, in partnership with the 
World Bank Group, launched the Global Financing Facility 
(GFF), the financing arm of Every Woman Every Child 
at the Third International Financing for Development 
Conference in 2015. The GFF is a new financing model for 
a different way of investing in health and development 
(panel). It uses a multistakeholder approach under 
country leadership, aiming to bring together the 
contributions in expertise and domestic and international 
resources of the World Bank Group, the UN, the Bill & 
Melinda Gates Foundation, The Partnership for Maternal, 
Newborn, Child and Adolescent Health (PMNCH), Gavi, 
the Vaccine Alliance, the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria, bilateral donors, private sector 
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Panel: Who is the GFF?
The Global Financing Facility (GFF) has been designed as a facility with country ownership 
at the heart. A country platform brings together the stakeholders who are part of the GFF, 
under government leadership. In most countries this is an existing structure, but a few 
countries have decided that no existing structure is quite right and have created a new 
platform for the GFF to ensure inclusivity and transparency.
The composition of these platforms differs in each of the GFF countries, but they all 
engage key donors, UN agencies, multilateral financiers (particularly, Gavi, the Vaccine 
Alliance, the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the World Bank), 
civil society organisations, and the private sector. In Kenya, for example, the partners’ 
consortium includes the UK’s Department for International Development, Japan 
International Cooperation Agency, Danida, UNAIDS, UN Population Fund, UNICEF, 
UN Women, United States Agency for International Development (USAID), WHO, 
the World Bank, and others. Civil society plays an important role in advocacy and 
accountability as well as in service delivery. More concerted efforts are needed to ensure 
that all aspects of the GFF process benefit from the engagement of civil society 
organisations, especially to hold all accountable.
Some countries have complemented the work of a formal country platform with 
additional broad-based consultations. In Cameroon, for example, the launch of the GFF 
process brought together approximately 200 people from various government ministries 
(and different administrative levels, with participation from government staff from across 
the country), civil society representatives, the private sector, and the full gamut of 
international partners in the country. Subsequent consultations were attended by 100 or 
more stakeholders, and dedicated events were held with groups such as the private sector. 
As the country has shifted into implementation in four priority regions, local level 
consultations are being held in those regions, chaired by regional governors to ensure a 
wide ownership of the process.
To help support and catalyse this, a multidonor trust fund—the GFF Trust Fund—has been 
established at the World Bank through generous contributions from the Governments of 
Canada and Norway and the Bill & Melinda Gates Foundation. Operationally, resources 
from the GFF Trust Fund are linked with concessional financing from the World Bank 
Group. To date, these have been linked in a ratio of US$1 from the trust fund to more than 
US$4 of concessional financing, reflecting grants signed in Cameroon, the Democratic 
Republic of Congo, Guatemala, Kenya, Liberia, Nigeria, Tanzania, and Uganda. Grants to 
Bangladesh, Ethiopia, Guinea, Mozambique, Myanmar, Senegal, and Vietnam have been 
or will be approved by the Bank’s Board in 2017.
For more on the Global 
Financing Facility see https://
www.globalfinancingfacility.org/
our-approach
